In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
All content for Divergent States is the property of Divergent States and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
Compass Pathways: Independent Media Talks Psychedelic Medicine
Divergent States
38 minutes
2 months ago
Compass Pathways: Independent Media Talks Psychedelic Medicine
In this episode of Divergent States, we sit down with Kabir Nath, CEO of Compass Pathways, and Dr. Steve Levine, Chief Patient Officer, to talk about the future of psychedelic medicine. From FDA approval and insurance coverage to patient access, cultural safety, and patents, we dig into whether Compass is truly disrupting the pharma model or just reinventing it. We also share a major community update: the official Divergent States Discord is now open to all of r/Psychonaut. Built by Brady and...
Divergent States
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
